Press release
T-cell Engagers Market to Record US$ 58.04 billion by 2035., Growth by Projection (2026 ) - Genmab A/S, Xencor Inc., Merus N.V., Immunocore Holdings plc, Gilead Sciences Inc
T-cell Engagers Market Size 2026-2035
Global T-cell Engagers Market stood at US$ 7.27 billion in 2025 and is projected to reach US$ 58.04 billion by 2035, growing at a CAGR of 22.73% during 2026-2035.
Download Free Sample Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/t-cell-engagers-market?kb
United States: Recent Industry Developments
✅ March 2026: Amgen Inc. advanced next-generation BiTE (bispecific T-cell engager) platforms targeting solid tumors, strengthening clinical pipeline expansion in oncology immunotherapy.
✅ February 2026: Regeneron Pharmaceuticals expanded its bispecific antibody manufacturing capabilities to support late-stage development programs in hematologic malignancies and solid tumor indications.
✅ January 2026: Johnson & Johnson (Janssen) progressed collaborative studies on T-cell engager combinations with checkpoint inhibitors to enhance durable anti-tumor responses.
✅ December 2025: MacroGenics, Inc. accelerated clinical evaluation of novel CD3-based T-cell engagers focused on improving tumor selectivity and reducing off-target toxicity.
Ready to scale in the T-cell Engagers Market? connect with the right partners and unlock new growth opportunities today:- https://www.datamintelligence.com/partner-identification-enquiry/t-cell-engagers-market?kb
List of Key Players 2026:
Amgen Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Genmab A/S, AbbVie Inc., Pfizer Inc., and Regeneron Pharmaceuticals Inc.
Leading Companies 2026:
Immunocore Holdings plc, Astellas Pharma Inc., Xencor Inc., and Merus N.V. are focusing on differentiated T-cell redirection approaches, novel therapeutic targets, and advanced drug formulation technologies as part of their strategic initiatives.
Other Key Players 2026:
Bristol Myers Squibb Company, GSK plc, and Gilead Sciences Inc., are strengthening their market position through oncology-focused drug pipelines, strategic collaborations, and ongoing immunotherapy research and development initiatives.
Key Strategic Growth Forecast Projections 2026:
The Global T-cell Engagers Market is entering a high-growth phase, with strong momentum expected throughout 2026-2035. Backed by accelerating industry adoption, strategic investments, and continuous innovation from leading players, the market is poised for significant expansion beyond its steady 2025 growth trajectory. The latest outlook highlights emerging opportunities, evolving competitive dynamics, and long-term revenue potential shaping the future of the industry.
Key Strategic Developments 2025-2026:
April 2026: Astellas Pharma and Vir Biotechnology entered into a global collaboration to develop VIR-5500, a PSMA-targeting dual-masked T-cell engager designed for prostate cancer treatment.
March 2026: Antengene out-licensed ATG-201, a CD19/CD3 bispecific T-cell engager for autoimmune diseases, to UCB for global development and commercialization.
February 2026: Boehringer Ingelheim and Zai Lab announced a strategic collaboration to develop a DLL3-targeting T-cell engager in combination with antibody-drug conjugate therapy.
January 2026: Johnson & Johnson expanded the clinical development of Tecvayli into earlier-line treatment settings for multiple myeloma through additional Phase III studies.
September 2025: Regeneron Pharmaceuticals secured FDA approval for linvoseltamab, a BCMA/CD3 T-cell engager indicated for relapsed multiple myeloma.
July 2025: Genmab and AbbVie expanded the clinical development of Epkinly through combination therapy trials targeting diffuse large B-cell lymphoma and follicular lymphoma.
May 2025: Pfizer advanced Elrexfio into wider global commercialization following expanded regulatory approvals across additional oncology markets.
How Our Market Research Process Works:
The global T-cell Engagers Market research report delivers strategic intelligence built through a robust blend of primary insights and extensive secondary research. The study provides a deep analysis of critical market forces shaping the industry, including regulatory developments, competitive positioning, evolving demand patterns, and historical market performance. It further highlights breakthrough technologies, innovation trends, and advancements across connected industries influencing the future of T-cell Engagers adoption. The report also uncovers high-growth opportunities, investment potential, market risks, and key operational challenges, enabling businesses to make faster, data-driven decisions in an increasingly competitive landscape.
Funding/M&A/partnerships 2025-2026:
• May 2026: UCB agreed to acquire Candid Therapeutics for up to $2.2B to expand its pipeline in next-generation T-cell engagers for autoimmune diseases
• May 2026: Gilead Sciences announced the acquisition of Ouro Medicines, strengthening its autoimmune-focused T-cell engager portfolio with BCMAxCD3 clinical-stage assets
• Jan 2026: Bristol Myers Squibb entered a collaboration with Janux Therapeutics worth up to $850M to develop tumor-activated T-cell engager therapies for solid tumors
• Jan 2026: Multiple pharma-biotech T-cell engager partnerships continued, with Janux advancing masked TCE platforms under expanded BMS development agreements
• Jan 2026: Eli Lilly strengthened immunology pipeline through broader autoimmune-focused deals aligned with T-cell based therapeutic platforms (TCE/bispecific expansion trend
Unlock & Get Full 360° Best Strategic Report: https://www.datamintelligence.com/buy-now-page?report=t-cell-engagers-market?kb
Japan: Recent Industry Developments
✅ March 2026: Chugai Pharmaceutical Co., Ltd. (Roche Group) strengthened its bispecific antibody pipeline, focusing on T-cell engager therapies for oncology precision treatment.
✅ February 2026: Takeda Pharmaceutical Company expanded strategic collaborations to develop T-cell engager-based immunotherapies targeting rare and refractory cancers.
✅ January 2026: Astellas Pharma advanced clinical programs integrating T-cell engaging antibody platforms to enhance immune-mediated tumor cell killing.
✅ December 2025: Daiichi Sankyo accelerated research in next-generation antibody-drug and T-cell engager hybrid constructs for solid tumor applications.
Major Segments Opportunity 2026:
By Molecule Type: Bispecific T-cell Engagers, Trispecific T-cell Engagers, Multispecific T-cell Engagers, T-cell Receptor Based Engagers, Antibody Fragment Based T-cell Engagers, and Full-Length Antibody Based T-cell Engagers
By Target Antigen: CD19, CD20, CD22, CD33, BCMA, GPRC5D, HER2, EGFR, PSMA, DLL3, CEA, Claudin 18.2, Mesothelin, and Others
By Therapy Type: Monotherapy and Combination Therapy
By Indication: Cancer, Autoimmune Diseases, Infectious Diseases, Fibrotic Disorders, Immune Mediated Disorders, Transplant Rejection, Rare Diseases, and Others
By Mechanism of Engagement: T-cell Redirecting Engagers, Tumor Specific T-cell Activation, Conditional Activation T-cell Engagers, Immune Synapse Enhancing Engagers, and Cytotoxic T-cell Recruitment Platforms
By Administration Route: Intravenous, Subcutaneous, Intratumoral, and Continuous Infusion
By Development Stage: Discovery Stage, Preclinical Stage, Phase I, Phase II, Phase III, and Commercialized Products
By End User: Hospitals, Specialty Cancer Centers, Academic Research Institutes, Biotechnology Companies, Pharmaceutical Companies, Contract Research Organizations, and Others
Regional Growth Intelligence for Market:
⇥ North America - Leads the T-cell engagers market due to strong presence of advanced oncology research, high adoption of immunotherapy treatments, and robust clinical trial activity.
⇥ Europe - Significant market supported by growing investment in cancer immunotherapy, expanding biopharmaceutical R&D, and increasing regulatory approvals.
⇥ Asia-Pacific - Rapidly growing region driven by rising cancer burden, improving healthcare infrastructure, and expanding access to novel biologics.
⇥ Latin America - Emerging market with increasing adoption of advanced oncology therapies and gradual expansion of specialty cancer treatment centers.
⇥ Middle East & Africa - Developing region with growing oncology awareness, improving hospital infrastructure, and increasing access to targeted immunotherapies.
Request Strategic Market Customization: https://datamintelligence.com/customize/t-cell-engagers-market?kb
FAQ's:
Q1: What is the current size of the T-cell Engagers Market?
A: The T-cell Engagers Market was valued at US$ 7.27 billion in 2025 and is projected to reach US$ 58.04 billion by 2035
Q2: How rapidly is the Market expanding?
A: The T-cell Engagers Market is expected to grow at a CAGR of 22.73% during the forecast period 2026 to 2035
Get Unlimited Market Reports & Strategic Insights: https://www.datamintelligence.com/reports-subscription?kb
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release T-cell Engagers Market to Record US$ 58.04 billion by 2035., Growth by Projection (2026 ) - Genmab A/S, Xencor Inc., Merus N.V., Immunocore Holdings plc, Gilead Sciences Inc here
News-ID: 4518846 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
United States Breast Cancer Treatment Market 2033 | Growth Drivers, Trends & Mar …
Market Size and Growth
The Global Breast Cancer Treatment Market reached USD 37.75 Billion in 2024 and is projected to grow significantly to USD 72.05 Billion by 2033, expanding at a CAGR of 9.4% during the forecast period (2025-2033).
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/breast-cancer-treatment-market?sb
The market is witnessing strong growth driven by rising adoption of precision oncology, targeted therapies, immunotherapy, and advanced…
Natural Gas Engine Market (2035): Industrial Engines, LNG Engines, Gasoline Engi …
Natural Gas Engine Market is estimated to reach USD 5.99 Billion in 2025 and is projected to grow to USD 10.65 Billion by 2035, registering steady growth at a CAGR of 5.9% during the forecast period from 2026 to 2035.
DataM Intelligence has released its latest research report, "Natural Gas Engine Market Size 2026." The study delivers an in-depth analysis of market dynamics, regional growth trends, segment performance, CAGR projections, competitive…
Myasthenia Gravis Therapeutics Market Size to Reach USD 3.48 Billion by 2033 Dri …
According to DataM Intelligence, the global myasthenia gravis therapeutics market was valued at USD 1.64 billion in 2025 and is projected to reach USD 3.48 billion by 2033, growing at a CAGR of 9.6% during the forecast period (2026-2033).
The market is witnessing steady growth due to the rising prevalence of autoimmune disorders, increasing awareness of early diagnosis, and growing adoption of targeted therapies for rare neurological diseases. Myasthenia gravis…
Weight Loss Therapeutics Market Size to Reach USD 20.84 billion by 2033, Driven …
According to DataM Intelligence, the global weight loss therapeutics market was valued at USD 4.73 billion in 2025 and is projected to reach USD 20.84 billion by 2033, growing at a robust CAGR of 20.6% during the forecast period (2026-2033).
Market growth is being fueled by the rising prevalence of obesity, increasing recognition of obesity as a chronic disease, and growing demand for effective non-surgical weight management solutions. Pharmaceutical companies…
More Releases for Engagers
Bispecific T-Cell Engagers Market Overview: Major Segments, Strategic Developmen …
The bispecific T-cell engagers market is rapidly evolving, driven by significant advancements in cancer immunotherapy and antibody engineering. This sector is gaining considerable traction as new therapies offer targeted treatment options for a range of malignancies. Let's explore the market's projected growth, leading companies, emerging trends, and key segments shaping this dynamic industry.
Projected Market Size and Growth Outlook for Bispecific T-Cell Engagers
The bispecific T-cell engagers market is anticipated to…
Future of T-cell Engagers Market (2035) | Bispecific T-cell Engagers, Oncology P …
DataM Intelligence has launched its latest research report, "T-cell Engagers Market Size 2026," offering comprehensive intelligence. The study delivers detailed analysis of market size, growth forecasts, regional opportunities, competitive landscape, revenue analysis of key industry participants, market segmentation, and emerging technology trends. Built to support strategic planning, market expansion, investment evaluation, and competitive analysis, the report provides actionable insights into evolving industry dynamics, future growth opportunities, and the long-term outlook…
What Are the Major Factors Accelerating Growth in the Bispecific T-cell Engagers …
Bispecific T-cell Engagers (BiTEs) market size reached US$ 2.63 Billion in 2025 from US$ 1.68 Billion in 2023 and is expected to reach US$ 15.76 Billion by 2033, growing at a CAGR of 25.1% during the forecast period 2026-2033.
Download Free Sample Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/bispecific-t-cell-engagers-bites-market?kb
United States: Recent Industry Developments
✅ March 2026: Amgen advanced its CD3-targeting BiTE pipeline, strengthening late-stage clinical programs focused on hematologic…
Leading Companies Fueling Innovation and Growth in the Bispecific T-Cell Engager …
The bispecific T-cell engagers market is positioned for remarkable growth in the coming years, driven by numerous advancements and expanding clinical applications. As the field of cancer immunotherapy evolves, these innovative therapies are becoming increasingly vital in targeting difficult-to-treat malignancies. Let's explore the market's size projections, key players, ongoing trends, and market segments shaping its promising future.
Projected Growth and Expansion of the Bispecific T-Cell Engagers Market
The bispecific T-cell…
Bispecific T-Cell Engagers (BiTEs) Market to Reach US$15.55 Billion by 2033, Exp …
The global Bispecific T-cell Engagers (BiTEs) market size reached US$ 2.10 billion in 2024 (from US$ 1.68 billion in 2023) and is expected to reach US$ 15.55 billion by 2033, growing at a CAGR of 25.1% from 2025 to 2033, according to DataM Intelligence.
United States: Recent Industry Developments
✅ In October 2025, Amgen expanded distribution of Blincyto (blinatumomab) to a majority of U.S. oncology centers and hospital systems, enhancing access for…
Immune Cell Engagers Market Innovation in Conditional Activation and Safety Engi …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Immune Cell Engagers (ICEs) Market Size, Share & Trends Analysis Report By Product Type (Bispecific Antibodies, Trispecific/Multispecific Antibodies, Engineered Cell Therapies), By Target Antigen (Oncology Targets, Autoimmune/Inflammatory Targets), By Mechanism of Action (Immune Cell Recruitment, Signal Modulation, Conditional Activtion), By Therapeutic Area (Oncology, Autoimmune/Inflammatory), Development Stage (Clinical Phase, Marketed/Approved),-Market Outlook And Industry Analysis 2035"
Immune…
